摘要
目的:通过测定慢性阻塞性肺疾病(COPD)患者血清中IL-32、8-iso-PGF2α水平,观察其在COPD不同时期中的变化及临床意义。方法:随机选取40例COPD患者,40例健康体检者作为对照组,通过酶联免疫法测定AECOPD、稳定期及健康对照组血清中IL-32及8-iso-PGF2α变化水平。结果:检测者血清中IL-32、8-iso-PGF2α水平健康对照组、COPD稳定期、AECOPD患者三组数据呈现逐渐增高趋势,即急性加重期高于稳定期,稳定期高于对照组。结论:血清中IL-32及8-iso-PGF2α在COPD的动态变化参数,为判断该疾病严重程度,并为临床治疗、评估治疗效果及出院后是否继续治疗提供理论依据。
Objective： To observe the changes and clinical significance in different periods of COPD through the determination of patients with chronic obstructive pulmonary disease （COPD） in serum IL - 32 and 8 - iso - PGF2 alpha level. Methods： We selected 40 cases of hospitalized patients with COPD and 40 healthy sub- jects as controls. We used enzyme-linked immunosorbent to assay the changes of serum IL-32 and 8-iso- PGF2a levels in AECOPD, stable and healthy controls. Results： The data of serum IL-32 and 8-iso- PGF2a levels in healthy controls, COPD stable, AECOPD patients showed a gradual increasing trend, that is, the data in acute exacerbation is higher than that in stable, and data in stable is higher than that in controls. Conclusion： The dynamic changes parameters of Serum IL-32 and 8-iso-PGF2a in COPD provide a theo- retical basis for judging the severity of the disease, and for clinical treatment, treatment effects assess and whether to continue treatment after discharge.
出处
《黑龙江医药科学》
2014年第2期6-7,共2页
Heilongjiang Medicine and Pharmacy
关键词
慢性阻塞性肺疾病
白介素32
8-异前列腺素
酶联免疫法
chronic obstructive pulmonary disease
IL- 32
8 - iso - PGF2a
enzyme - linked im- munosorbent assay
